http://purl.uniprot.org/citations/30518758 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
http://purl.uniprot.org/citations/30518758 | http://www.w3.org/2000/01/rdf-schema#comment | "Deciphering cell-intrinsic mechanisms of metastasis progression in vivo is essential to identify novel therapeutic approaches. Here we elucidate cell-intrinsic drivers of metastatic prostate cancer progression through analyses of genetically engineered mouse models (GEMM) and correlative studies of human prostate cancer. Expression profiling of lineage-marked cells from mouse primary tumors and metastases defines a signature of de novo metastatic progression. Cross-species master regulator analyses comparing this mouse signature with a comparable human signature identifies conserved drivers of metastatic progression with demonstrable clinical and functional relevance. In particular, nuclear receptor binding SET Domain Protein 2 (NSD2) is robustly expressed in lethal prostate cancer in humans, while its silencing inhibits metastasis of mouse allografts in vivo. We propose that cross-species analysis can elucidate mechanisms of metastasis progression, thus providing potential additional therapeutic opportunities for treatment of lethal prostate cancer."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.org/dc/terms/identifier | "doi:10.1038/s41467-018-07511-4"xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Rubin M.A."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Shen M.M."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Califano A."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Abate-Shen C."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Aytes A."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Ruggero K."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Giacobbe A."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Mitrofanova A."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Cyrta J."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Palomero L."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Arriaga J."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/author | "Farran-Matas S."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/date | "2018"xsd:gYear |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/name | "Nat Commun"xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/pages | "5201"xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/title | "NSD2 is a conserved driver of metastatic prostate cancer progression."xsd:string |
http://purl.uniprot.org/citations/30518758 | http://purl.uniprot.org/core/volume | "9"xsd:string |
http://purl.uniprot.org/citations/30518758 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/30518758 |
http://purl.uniprot.org/citations/30518758 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/30518758 |
http://purl.uniprot.org/uniprot/#_A0A024QYR9-mappedCitation-30518758 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30518758 |
http://purl.uniprot.org/uniprot/#_A0A0J9YUM7-mappedCitation-30518758 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30518758 |
http://purl.uniprot.org/uniprot/#_A0A0N4SVY1-mappedCitation-30518758 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30518758 |